Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,070 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis.
Kaufmann JE, Harshfield EL, Gensicke H, Wegener S, Michel P, Kägi G, Nedeltchev K, Kellert L, Rosenbaum S, Nolte CH, Christensen H, Arnold M, Lyrer P, Levi C, Bath PM, Engelter ST, Traenka C, Markus HS; CADISS and TREAT-CAD Investigators. Kaufmann JE, et al. JAMA Neurol. 2024 Jun 1;81(6):630-637. doi: 10.1001/jamaneurol.2024.1141. JAMA Neurol. 2024. PMID: 38739383
Crimean-Congo Hemorrhagic Fever Virus for Clinicians-Diagnosis, Clinical Management, and Therapeutics.
Frank MG, Weaver G, Raabe V; State of the Clinical Science Working Group of the National Emerging Pathogens Training; Education Center’s Special Pathogens Research Network2; State of the Clinical Science Working Group of the National Emerging Pathogens Training Education Center’s Special Pathogens Research Network. Frank MG, et al. Emerg Infect Dis. 2024 May;30(5):864-873. doi: 10.3201/eid3005.231648. Emerg Infect Dis. 2024. PMID: 38666553 Free PMC article. Review.
Crimean-Congo Hemorrhagic Fever Virus for Clinicians-Epidemiology, Clinical Manifestations, and Prevention.
Frank MG, Weaver G, Raabe V; State of the Clinical Science Working Group of the National Emerging Pathogens Training; Education Center’s Special Pathogens Research Network2; State of the Clinical Science Working Group of the National Emerging Pathogens Training Education Center’s Special Pathogens Research Network. Frank MG, et al. Emerg Infect Dis. 2024 May;30(5):854-863. doi: 10.3201/eid3005.231647. Emerg Infect Dis. 2024. PMID: 38666548 Free PMC article. Review.
SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir.
Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, Laverdure S, Highbarger H, Lallemand P, Huang ML, Jerome KR, Sampoleo R, Mills MG, Greninger AL, Juneja K, Porter D, Benson CA, Dempsey W, El Sahly HM, Focht C, Jilg N, Paules CI, Rapaka RR, Uyeki TM, Lane HC, Beigel J, Dodd LE; Adaptive COVID-19 Treatment Trial (ACTT-1) Study Group Members. Singh K, et al. J Infect Dis. 2024 Apr 24:jiae198. doi: 10.1093/infdis/jiae198. Online ahead of print. J Infect Dis. 2024. PMID: 38657001
Single-cell image-based genetic screens systematically identify regulators of Ebola virus subcellular infection dynamics.
Carlson RJ, Patten JJ, Stefanakis G, Soong BY, Radhakrishnan A, Singh A, Thakur N, Amarasinghe GK, Hacohen N, Basler CF, Leung D, Uhler C, Davey RA, Blainey PC. Carlson RJ, et al. Among authors: davey ra. bioRxiv [Preprint]. 2024 Apr 7:2024.04.06.588168. doi: 10.1101/2024.04.06.588168. bioRxiv. 2024. PMID: 38617272 Free PMC article. Preprint.
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S, Bressel M, Sidhom M, Sridharan S, Vanneste BGL, Davey R, Montgomery R, Ruben J, Foroudi F, Higgs B, Lin C, Raman A, Hardcastle N, Hofman MS, De Abreu Lourenco R, Shaw M, Mancuso P, Moon D, Wong LM, Lawrentschuk N, Wood S, Brook NR, Kron T, Martin J, Pryor D; FASTRACK II Investigator Group. Siva S, et al. Among authors: davey r. Lancet Oncol. 2024 Mar;25(3):308-316. doi: 10.1016/S1470-2045(24)00020-2. Lancet Oncol. 2024. PMID: 38423047 Clinical Trial.
A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
Paules CI, Wang J, Tomashek KM, Bonnett T, Singh K, Marconi VC, Davey RT Jr, Lye DC, Dodd LE, Yang OO, Benson CA, Deye GA, Doernberg SB, Hynes NA, Grossberg R, Wolfe CR, Nayak SU, Short WR, Voell J, Potter GE, Rapaka RR. Paules CI, et al. Among authors: davey rt jr. Ann Intern Med. 2024 Mar;177(3):343-352. doi: 10.7326/M23-2593. Epub 2024 Feb 27. Ann Intern Med. 2024. PMID: 38408357 Free article. Clinical Trial.
1,070 results